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doi:10.1016/j.jmii.2011.01.009Background: Tigecycline was approved for the treatment of complicated intra-abdominal and
complicated skin/skin structure infections. Because of its in vitro effectiveness for multidrug-
resistant (MDR) isolates, tigecycline has been prescribed more broadly. This study evaluated
tigecycline use after its first introduction in Taiwan and experience with tigecycline for
the treatment of MDR Acinetobacter baumannii (MDRAB) infection, especially for ventilator-
associated pneumonia.
Methods: Patients treated with tigecycline were collected retrospectively from February 2008
to July 2008 in Taipei Veterans General Hospital, a 2,900-bed tertiary care medical center in
Taiwan. Patients were divided into three groups according to the indications: Group 1, Food
and Drug Administrationeapproved indications; Group 2, health careeassociated pneumonia
(HAP); and Group 3, urinary tract infection, osteomyelitis, bacteremia, etc. Cases of MDRAB
were also identified.
Results: Among 66 cases, indications for the administration of tigecycline included Food and
Drug Administrationeapproved indications (12, 18.2%), HAP (38, 57.6%), bacteremia (3, 4.5%),
catheter-related infections (3, 4.5%), urinary tract infection (4, 6.1%), osteomyelitis
(4, 6.1%), and others (2, 3%). Clinical outcome was positive in 20 cases, with higher clinical
success rate for Group 1 than Group 2, which may correlate with higher Sequential Organ FailureInfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, 201 Shih-Pai Road
v.tw (F.-D. Wang).
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46 S.-C. Kuo et al.Table 1 Microbiological eradica
Diagnosis
cIAI
cSSSI
HAP
Bacteremia
Catheter-related bacteremia
UTI
Osteomyelitis
Others
cIAIZ complicated intra-abdominal
pneumonia; UTIZ urinary tract infeAssessment score, older age, and more frequent intensive care admission in Group 2. Of the
microbiologically evaluable cases, MDRAB predominated (33/51, 64.7%). Among infections with
MDRAB (excluding pneumonia without ventilator), the clinical success rate was 12% (3/25).
Conclusions: The most common indication for the prescription of tigecycline was HAP. Success
rate for MDRAB infection was lower than that previously reported, possibly because of serious
underlying conditions and comorbidities in our patients. Because of limited choices, physicians
should weigh the risk and benefit for prescribing tigecycline.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Tigecycline, the first of the glycylcyclines, was approved by
the US Food and Drug Administration (FDA) for treatment of
complicated intra-abdominal infection (cIAI) and compli-
cated skin and skin structure infection (cSSSI).1 Because of
substitution of a N-alkyl-glycylamido group on the D ring at
the ninth position, tigecycline can evade efflux pumps and
ribosomal protectionmechanisms associatedwith resistance
to the tetracycline class and has a broader spectrum of
activity.1,2 In addition to methicillin-resistant Staphylo-
coccus aureus, tigecycline is also highly active in vitroagainst
a variety of multidrug-resistant (MDR) clinical isolates,
including glycopeptide-intermediate S aureus, penicillin-
resistant Streptococcus pneumoniae, vancomycin-resistant
enterococci and extended-spectrum b-lactamaseeproduc-
ing Escherichia coli, andKlebsiella pneumoniae.1,3,4 In vitro,
it also showed bacteriostatic activity against Acinetobacter
baumannii, an emerging cause of nosocomial infections.5
With increasing frequency because of more vulnerable
hosts and the ability to accumulate different mechanisms of
resistance,Abaumannii appears to be the species of greatest
clinical importance.6,7 Multiple drug resistance to poten-
tially effective antibiotics such as carbapenems, amino-
glycosides, tetracyclines, fluoroquinolones, sulbactam,
antipseudomonal penicillins, and broad-spectrum cephalo-
sporins has been reported more frequently, mandating the
introduction of combination therapy and novel antibiotics
including glycylcyclines and polymyxins.8e10 Favorable clin-
ical outcomes of MDR A baumannii (MDRAB) treated with
tigecycline have been reported in several studies, although
rapidly emerging resistance and failure to eradicate A bau-
mannii have also been reported.4,9,11 Because the experi-
ence with tigecycline for treating MDRAB infections is never
reported inTaiwan,we identifiedandanalyzeddata for casestion and clinical success rate b
Total population, n (%) Clin
1 (1.5) 0/1
11 (16.7) 8/11
38 (57.6) 7/38
3 (4.5) 0/3
3 (4.5) 1/3
4 (6.1) 1/4
4 (6.1) 2/4
2 (3.0) 1/2
infection; cSSSIZ complicated s
ction.treated with tigecycline after its first introduction, espe-
cially in treatment of critically ill and elderly patients with
MDRAB infection.
Material and methods
Study design and patients
This retrospective review was conducted at the Taipei
Veterans General Hospital, a 2,900-bed tertiary care
medical center in Taiwan, from February 2008 to July 2008.
All patients who received tigecycline for more than 72
hours regardless of infection type were identified. Age, sex,
underlying diseases, admission settings (intensive care unit
or general ward), indication for tigecycline use, Sequential
Organ Failure Assessment (SOFA) score, and microbiological
and clinical outcomes were documented. Previous and
concomitant antimicrobial agents administered for more
than 3 days were also recorded.
Patients were placed into one of three groups according
to the indications for tigecycline use: Group 1, FDA-
approved indications (cIAI and cSSSI); Group 2, health
careeassociated pneumonia (HAP); and Group 3, urinary
tract infection (UTI), osteomyelitis, bacteremia, or others.
HAPwas defined as the presence of clinical symptoms and
signs as well as radiographic evidence of pneumonia in
patients who were hospitalized for more than 3 days, who
were transferred from another health care facility or who
had prior hospitalization within 30 days. Ventilator-associ-
ated pneumonia (VAP) was diagnosed by the presence of
clinical symptoms and signs as well as radiographic evidence
of pneumonia after initiation of mechanical ventilation.
Bacteremia was defined as isolation of bacteria from blood
culture, along with clinical symptoms and signs of systemic
infection. UTI was diagnosed based on isolation of bacteriay primary diagnosis
ical success, n/N (%) Microbiological eradication, n/N (%)
(0) 0/1 (0)
(72.7) 7/11 (63.6)
(18.4) 6/38 (15.8)
(0) 0/3 (0)
(33.3) 1/3 (33.3)
(25) 1/4 (25)
(50) 2/4 (50)
(50) 1/2 (50)
kin and skin structure infection; HAPZ health careeassociated
Tigecycline for elderly and critically ill patients 47with concurrent pyuria. cSSSI was defined as infection
requiring significant surgical intervention, involving deeper
soft tissue, or accompanied by a significant underlying
disease (diabetes mellitus, peripheral vascular disease, or
lower extremity venous insufficiency) that complicates
response to treatment. Sputum of adequate quality, lower
respiratory tract secretions, or samples from sterile siteswas
sent for culture. Identification of bacteriawasdeterminedby
phenotypic methods. All patients received a 100-mg loading
dose followed by a 50-mg twice-daily maintenance dose.
We also analyzed the subgroup infections of MDRAB.
MDRABwasdefinedasanyAbaumannii isolatenot sensitive to
three or more antimicrobial classes including carbapenems,
aminoglycosides, fluoroquinolones, sulbactam, anti-
pseudomonal penicillins, and broad-spectrum cephalospo-
rins, whereas extensive drug resistance (XDR) was defined as
any microorganism not susceptible to any of the above-
mentioned antimicrobial agents. Concurrent antibiotics
directed against A baumannii were recorded if administered
for more than 72 hours.
Clinical outcome
Clinical cure was defined as resolution of signs and symptoms
of infection andno further antibiotics administered for 3 days
after the discontinuation of tigecycline. Continued presence
of symptoms and signs of the infection that mandated
discontinuation of tigecycline andaddition of other antibiotic
therapy, or death, was considered clinical failure.
Microbiological outcome
Cases that showed clinical success were followed for 1 week.
Microbiological eradicationwasdefinedas negative culture in
repeat cultures or clinical cure making a repeat culture
unnecessary. Different isolates from any site or the same
pathogen fromadifferent sitewith concurrent symptoms and
signs of infection was considered new infection. The same
isolate from the original site was considered recurrence.
All subjects with clinical failure were also followed for
1 week. Presence of the baseline isolate in the repeat
cultures from the original site or no culture data being
available after clinical failure was considered persistence.
Superinfection was defined as a new isolate obtained during
the treatment of the original infection with development of
symptoms and signs of clinical infection.
Data analysis
Qualitative variables were compared by the Pearson chi-
squared or Fisher exact test, and quantitative variables
were compared by Kruskal-Wallis one-way test. For all
analyses, a p value of <0.05 was considered significant for
two-tailed tests.
Results
A total of 100 instances of tigecycline therapy at our
institution were identified for the study period beginning
with drug introduction in Taiwan. Thirty-four episodes were
excluded because of duration of less than 72 hours orincomplete data collection. Sixty-five different patients
with 66 episodes of tigecycline use were analyzed in this
study. One patient had two episodes of infection including
cIAI and HAP. Both were treated with tigecycline and
referred as two episodes.
Antibiotic use for FDA-approved indications accounted for
12 cases (18.2%). Most cases (54/66, 81.8%) received tige-
cycline for off-label indications, including HAP (38, 57.6%),
bacteremia (3, 4.5%), catheter-related infection (3, 4.5%),
UTI (4, 6.1%), osteomyelitis (4, 6.1%), and others (2, 3%).
Mean age of the 65 patients was 74.2 16.1 years. Patients
with Group 2 indications were older than those with Group 1
indications (78 years vs. 65 years, p< 0.05). Median duration
of hospital staywas 49 days (range 8e533)without significant
differences among the three groups (pZ 0.359). Fifty cases
(75.8%) were male. Forty-seven patients (71.2%) were
admitted to a medical service, whereas 38 patients (57.6%)
received tigecycline in the intensive careunit. Therewereno
significant differences between the three groups regarding
proportion with medical ward admission (pZ 0.087). The
proportion of patients who had intensive care unit stays
during tigecycline treatmentwas higher among patientswith
Group 2 indications than those with Group 1 or Group 3
indications (76.3% vs. 16.7% and 43.8%, respectively,
p< 0.05). The average SOFA score was 7.1 5.1. Patients
with Group 2 indications had higher SOFA score than those
with Group 1 (8.6 vs. 2.8, p< 0.05). Median duration of
tigecycline therapy and hospitalization before tigecycline
use were 12 days (range 3e77) and 24 days (range 0e445),
respectively, without significant differences among the
three groups (pZ 0.46 and 0.1).
Only two cases did not receive antibiotics before tigecy-
cline therapy. There were no significant differences among
the three groups about the portion of patients with previous
antibiotic therapy (pZ 0.67). Combination therapywas used
in 43 cases. Patients with Group 2 indications had concurrent
antibiotic treatment more frequently than those with
Group 1 (73.7% vs. 25%, respectively, p< 0.05). Among 66
total episodes of tigecycline use, 51 pathogens were identi-
fied. Themost commonly isolated organismwas A baumannii
(34/51, 66.7%). MDRAB was identified in 33 cases and more
commonly isolated in Group 2 indications than Group 1 or
Group 3 (65.8% vs. 25.0% and 31.3%, respectively, p< 0.05).
XDR A baumannii (XDRAB) was identified in 16 patients
(31.4%). There were 14 patients with polymicrobial infec-
tions. The majority (11/14, 78.6%) had Group 2 indications.
Methicillin-resistant S aureus was the most common
concurrent pathogens (7/14, 50%). Two patients had
concurrent candidal infections, and both had unfavorable
clinical outcomes. Other pathogens included K pneumoniae
(including one with extended-spectrum b-lactamase),
Citrobacter spp, Serratia spp, and Stenotrophomonas mal-
tophilia. One patient with coexisting Pseudomonas aerugi-
nosa infection was concurrently treated with ceftazidime,
and one with Providencia stuartii infection was treated with
cefepime.
Details of clinical outcomes and microbiological eradi-
cations are listed in Table 1. Twenty cases achieved clinical
success, with 18 microbiological eradications and two new
infections. The clinical success rate was higher in Group 1
indications than in Group 2 (66.7% vs. 18.4%, p< 0.05). Of
those with clinical failure, 30 cases had persistent
Table 2 Characteristics of 25 cases with multidrug-resistant Acinetobacter baumannii infection treated with tigecycline alone or in combination with other antimicrobials
Patient no. Age
(yr)/sex
Comorbid condition Type of
infection
Tigecycline
alone or
combination
therapy
Duration of
therapy (d)
Microbiological
outcome
Clinical
outcome
Final
disposition
1 83/M CVA, bilateral hemothorax
and right pneumothorax, CRI,
pituitary macroadenoma
VAP Sulbactam 14 Negative Negative Died
2 89/M CVA, septic shock, CRI VAP Tigecycline
monotherapy
5 Negative Negative Died
3 81/M NSTEMI status post CABG,
COPD, CRI
VAP Tigecycline
monotherapy
14 Negative Negative Alive
4 77/M CHF, COPD, CRI, PAOD VAP Tigecycline
monotherapy
3 Negative Negative Died
5 91/M CHF, CAD, COPD, CRI, ARDS VAP Sulbactam 12 Negative Negative Died
6 84/M CVA, COPD, old TB with
left destructive lung, CRI
VAP Sulbactam 13 Negative Negative Died
7 94/F CVA, CHF, septic shock VAP Tigecycline
monotherapy
11 Negative Negative Died
8 91/M DM, ESRD under hemodialysis VAP Cefepime 3 Negative Negative Died
9 78/F Myelodysplastic syndrome,
Alzheimer’s disease
VAP Tigecycline
monotherapy
6 Negative Negative Alive
10 60/M CVA, nasopharyngeal carcinoma
s/p radiotherapy, rheumatic
heart disease with severe mitral
valve stenosis s/p mitral valve
replacement, chronic
tracheostmoy and ventilator use
VAP Tigecycline
monotherapy
5 Negative Negative Alive
11 82/M DM, CHF, NSTEMI, CRI, ARDS VAP Tigecycline
monotherapy
14 Negative Negative Died
12 53/M Liver cirrhosis, squamous cell
carcinoma of esophagus,
gastric tube perforation,
and right side empyema
VAP Ampicillin/
sulbactam
14 Negative Negative Died
13 91/M DM, CHF, valvular heart
disease with pulmonary
hypertension, COPD, ARF
VAP Cefepime 3 Negative Negative Died
14 70/M DM, CVA, COPD, papillary
urothelial carcinoma of
urinary bladder, gastric
adenocarcinoma, chronic
tracheostomy use
VAP Imipenem 7 Negative Positive Died
15 78/M Adenocarcinoma of lung with
multiple metastasis
under gefitinib use
VAP Piperacillin/
tazobactam
10 Negative Negative Died
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16 91/M CVA, right pneumothorax VAP Cefepime 14 Negative Negative Alive
17 82/F DM, infrarenal abdominal aortic
aneurysm rupture s/pt
emergent graft repair
VAP Ampicillin/
sulbactam
19 Negative Negative Died
18 53/F DM, uterine malignant mixed
mullerian tumor with
carcinomatosis
VAP Piperacillin/
tazobactam
5 Negative Negative Died
19 76/M Spinal stenosis, lumbar
osteomyelitis with epidural
abscess, septic shock, CRI
UTI Piperacillin/
tazobactam,
then imipenem
and sulbactam
12 Negative Negative Alive
20 50/M Gastric perforation with
gastrojejunostomy
and feeding jejunostomy
cSSSI Ceftazidime
and then
aztreonam
27 Negative Negative Died
21 76/F Perforation of ileum with
localized abscess and
intestinal obstruction,
utero-sigmoid fistula,
severe mitral
regurgitation
Catheter-
related
bacteremia
Imipenem 4 Positive Positive Alive
22 86/M Septic shock, recurrent
right hip cellulitis and
osteomyelitis with abscess
and fistula formation,
leprosy, dementia in
bedridden status
cSSSI Tigecycline
monotherapy
23 Negative Positive Died
23 84/M Proximal sigmoid colon
perforation with peritonitis,
chronic tracheostomy and
ventilator, septic shock
Bacteremia Tigecycline
monotherapy
21 Negative Negative Alive
24 80/M DM, gastric ulcer with
uncontrolled bleeding
s/p radical total
gastrectomy, bladder
neck cancer
Bacteremia Sulbactam 9 Negative Negative Alive
25 79/M CVA, multiple pressure
sores, PAOD with right
foot gangrene, old
pulmonary
TB, septic shock
cSSSI Tigecycline
monotherapy
15 Negative Negative Died
ARDSZ acute respiratory distress syndrome; ARFZ acute renal failure; CABGZ coronary artery bypass graft; CADZ cardiovascular disease; CHFZ congestive heart failure;
COPDZ chronic obstructive pulmonary disease; CRIZ chronic renal insufficiency; cSSSIZ complicated skin and skin structure infection; CVAZ cerebrovascular accident;
DMZ diabetes mellitus; ESRDZ end-stage renal disease; MIZmyocardial infarction; NSTEMIZ non-ST elevation myocardial infarction; PAODZ peripheral arterial occlusive disease;
TBZ tuberculosis; UTIZ urinary tract infection; VAPZ ventilator-associated pneumonia.
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50 S.-C. Kuo et al.infection, 15 had superinfection, and one could not be
defined because resolution of fever was not achieved by
empirical use of tigecycline for fever of unknown origin.
MDRAB infections
Eight patients with pneumonia but without ventilator use
were excluded because patients of this type were not
widely discussed in most previous studies.9 We identified 25
patients who received tigecycline for the treatment of
MDRAB infection. Eighteen patients (72%) received tigecy-
cline for the treatment of VAP, three (12%) for cSSSI, three
(12%) for bacteremia (including one case of catheter-
related bacteremia), and one (4%) for UTI. These patients
had a mean age of 78.4 12.4 years and median length of
stay of 53 days (range 9e175). The average of SOFA score
was 9.5 4.5. Nearly all of patients (24/25, 96%) received
mechanical ventilation during tigecycline treatment.
Median duration of hospitalization before initiation of
tigecycline was 21 days (range 2e74), and median treat-
ment duration was 9.5 days (range 3e27). Polymicrobial
infections were identified in eight patients (32%) and not
associated with worse clinical outcomes (pZ 1.00). XDRAB
was identified in 13 patients (52%). Among patients with
VAP, the average age was 79.3 12.7 years and the mean
SOFA score was 9.9 4.2.
Ten patients were treated with tigecycline monotherapy
and 15 with combination therapy. Single combination
therapy was used in 13 cases, including sulbactam (6/25,
24%), piperacillin/tazobactam (2/25, 8%), cefepime (3/25,
12%), and imipenem (2/25, 8%). Two patients received
combination therapy consisting of one regimen after
another, one receiving ceftazidime followed by aztreonam
and the other receiving piperacillin/tazobactam followed
by imipenemþ sulbactam. The sole patient with successful
clinical and microbiological outcomes was treated with
tigecycline and imipenem. One patient experienced
thrombocytopenia (148,000e48,000/mL); no other adverse
events were reported.
Clinical and microbiological outcomes are listed in
Table 2. Clinical success was achieved in only three (12%)
patients. Microbiological eradication was seen in one case,
and new infections (Burkholderia cepacia bacteremia and
P aeruginosa urosepsis) were identified in the others.
Tigecycline failed clinically in 22 patients (88%), consisting
of 18 persistent infections and four superinfections. Two
cases with pneumonia developed bacteremia, one with
Chryseobacterium meningosepticum and one with Chrys-
eobacterium indologenes. Seventeen (68%) patients did not
survive to discharge.
Discussion
In the present study, we demonstrated the effectiveness of
tigecycline in clinical practice after its first introduction.
However, because of the retrospective nature, suscepti-
bility result of tigecycline was not available. The 18.2% use
of tigecycline for FDA-approved indications may be
explained by availability of other effective therapeutic
options for cSSSI and cIAI.12 Tigecycline was an alternative
antimicrobial agent for cIAI in Taiwan.13 Most cases (81.8%)received tigecycline for off-label use, especially for HAP
(57.6%). Similarly in Argentina, 78% of the tigecycline
prescriptions were for off-label use during its first month of
commercial use, especially for VAP (61%) due to MDR Aci-
netobacter spp infection.14
In our study, cases with HAP were older (mean age 78
years), were more frequently admitted to the intensive
care unit (76.3%), and had higher SOFA score (mean 8.6).
Prior antibiotic use was found in almost all cases. Further-
more, MDRAB was more common (65.8%) in patients with
Group 2 indications. In such severely ill patients who had
experienced multiple antibiotics and infected by MDRAB,
therapeutic options were relatively limited and mortality
was high.8,10,11,15,16 Although new agents as well as new
strategies and reintroduction of antibiotics have been
developed, most of the clinical studies were of small sizes
and not randomized.5,8-10 Because no comparative trial was
conducted, tigecycline is one of the drug choices for such
critically ill patients.4,5,9,11 That may also be the reason
why concurrent antibiotics were used more frequently in
patients with the Group 2 indications.
The overall clinical success rate in our study was 30.3%.
The clinical success rate was significantly higher for FDA-
approved indications than for HAP (66.7% vs. 18.4%). Among
cases infected with MDRAB, the clinical success rate was
only 12%, and for VAP caused by MDRAB, the success rate
was 5.6% (1/18), a finding that was quite different from the
results of other studies.4,9,11,14 Anthony et al.4 reported
a clinical success rate of 50% (5/10) for serious infections
with A baumannii. Schafer et al.11 also reported 84% (21/
25) of patients with VAP and/or bacteremia caused by
MDRAB had clinical resolution. The overall clinical success
in 86 of the 113 (76.1%) patients treated with tigecycline
after its first commercialization in Argentina was reported,
whereas clinical success rate in patients with VAP caused by
MDRAB was 64% (32/50).14 However, one study showed
unfavorable clinical outcome (28%) in patients with pneu-
monia, bacteremia, and UTI caused by Acinetobacter spp.17
The poor outcomes in our study may be because of multiple
factors. Not only with many comorbidities and ventilator
use, our patients were also critically ill and aged. The
length of overall hospitalization and duration before tige-
cycline administration were long, implying serious under-
lying conditions in our patients. In addition, the definition
of clinical success in our study was stricter. The clinical
success rate increased to 28% (7/25 for MDRAB infections)
and 22.2% (4/18 for VAP), if the change of antibiotics was
because of persistence of previous infection but not
superinfections, as previous studies described.4,11,14 The
XDRAB rate was also high (13/25, 52%) in our series, which
may cause adverse impacts on the clinical consequences
because of inappropriate therapy.18 It is difficult to analyze
all factors associated with clinical outcomes because of
relatively small number of patients and diversity of
underlying diseases.
Although some clinical studies had positive findings,4,17
the clinical outcomes of one episode of UTI, two episodes
of bacteremia, and one episode of catheter-related
bacteremia because of MDRAB were all poor in our study.
Tigecycline is mainly excreted through the gastrointestinal
tract, with less than 15% of an administered dose excreted
unchanged in the urine and serum concentration is also
Tigecycline for elderly and critically ill patients 51suboptimal for antibacterial activity.19,20 It has been
reported that bloodstream infections were caused by tige-
cycline-nonsusceptible A baumannii in patients receiving
tigecycline for other indications.21 The use of tigecycline
for treating UTI and bloodstream infections should be more
cautious.4 Several patients in the present study had
bacteremia or UTI caused by C indologenes, XDRAB, or
vancomycin-resistant enterococci.
Although tigecycline is in vitro and in vivo active against
many MDR organisms, it has limited activity against P aer-
uginosa, indole-positive Proteae, and Proteus mirabilis.1 Of
our cases with clinical success, two developed new infec-
tions, one with B cepacia bacteremia and one with Pseu-
domonas urosepsis, after tigecycline use. Of cases with
microbiological failure, one with bacteremia of C menin-
gosepticum and one with C indologenes were found.
Superinfection with tigecycline-nonsusceptible A bau-
mannii during tigecycline use for other indications has been
reported, but superinfection with other strains has not
been reported.21
The most common side effects of tigecycline including
nausea and vomiting in a previous study22 could not be
accessed in most of our patients because they either had
old cerebrovascular diseases or were intubated. There was
no documented serious adverse effect associated with
tigecycline use except thrombocytopenia in one patient.
In conclusion, the most common indication for tigecy-
cline prescription was not cIAI or cSSSI but HAP in our
institution. The success rate was higher for FDA-approved
indications than that for HAP. Although the success rate
with tigecycline was not as effective as previous studies
reported, serious underlying conditions and comorbidities
in our patients may be the culprit. In view of limited drug
choices and high mortality in such critically ill and aged
patients with infection caused by MDRAB, tigecycline may
be one of the alternative choices.
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